June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
The Impact of Compartmental Exudative Volatility on Visual Acuity Outcomes in Neovascular AMD
Author Affiliations & Notes
  • Justis P Ehlers
    Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • Leina Lunasco
    Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • Sari Yordi
    Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • Hasan Cetin
    Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • Kubra Sarici
    Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • Thuy K Le
    Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • Katherine E Talcott
    Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • Robert Zahid
    Novartis AG, Basel, Basel-Stadt, Switzerland
  • Joanne Hu
    Novartis AG, Basel, Basel-Stadt, Switzerland
  • Xiangyi Meng
    Novartis AG, Basel, Basel-Stadt, Switzerland
  • Peter K Kaiser
    Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • Arshad M. Khanani
    Sierra Eye Associates, Nevada, United States
  • Sunil K Srivastava
    Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • Footnotes
    Commercial Relationships   Justis Ehlers Aerpio, Alcon, Allegro, Allergan, Genentech/Roche, Novartis, Thrombogenics/Oxurion, Leica, Zeiss, Regeneron, Santen, Stealth, Adverum, IvericBIO, Apellis, Boehringer-Ingelheim, RegenxBIO, Code C (Consultant/Contractor), Aerpio, Alcon, Thrombogenics/Oxurion, Regeneron, Genentech, Novartis, Allergan, Boehringer-Ingelheim, IvericBio, Adverum, Code F (Financial Support), Leica, Code P (Patent); Leina Lunasco None; Sari Yordi None; Hasan Cetin None; Kubra Sarici None; Thuy Le None; Katherine Talcott Zeiss, Novartis, RegenxBio, Code F (Financial Support); Robert Zahid Novartis, Code E (Employment); Joanne Hu Novartis, Code E (Employment); Xiangyi Meng Novartis, Code E (Employment); Peter Kaiser Aerie, Allegro, Allergan, Allgenesis, Alzheon, Annexon Biosciences, AsclepiX, Aviceda, Bayer, Bausch and Lomb, BIogen Idec, Bionic Vision Technologies, Boehringer Ingelheim, Zeiss, Clearside, DelSiTech, DTx Pharma, Duet Therapeutics, Eyevensys, Galecto Biotech, Galimedix, Gemini, Glaukos, Innovent, iRenix, Iveric Bio, jCyte, Kanaph Therapeutics, Kanghong, Kodiak, LensGen, NGM Biopharamaceuticals, Novartis, Ocugenix, Oculis, Ocuphire, OcuTerra Therapeutics, Omeros, Ophthea, Oxurion, Palatin, Regeneron, Retinal Sciences, Retrope, Roivant, Samsung, Sandoz, Santen, Stealth, Sustained Nano Systems, Takeda, Thea, 2020 Onsite, Code C (Consultant/Contractor); Arshad Khanani 4DMT, Adverum, Aerpio, Alcon, Allergan, Apellis, Broadwing Bio, DORC, Gemini, Genentech, Graybug, Gyroscope, Iveric Bio, Kato, Kodiak, Novartis, Opthea, Oxurion, PolyPhotonix, Recens Medical, Regenxbio, Surrozen, Code C (Consultant/Contractor), Adverum, Alkahest, Allergan, Annexon, Gemini Genentech, Gyroscope, Iveric Bio, Kodiak, NGM Pharmaceuticals, Novartis, Opthea, Ophthotech, Oxurion, Recens Medical, Regenxbio, Code F (Financial Support); Sunil Srivastava Bausch and Lomb, Adverum, Novartis, and Regeneron. , Code C (Consultant/Contractor), Regeneron, Allergan, and Gilead;, Code F (Financial Support)
  • Footnotes
    Support  Novartis Grant, NIH-NEI P30 Core Grant (IP30EY025585) (Cole Eye) Unrestricted Grants from The Research to Prevent Blindness, Inc (Cole Eye); Cleveland Eye Bank Foundation awarded to the Cole Eye Institute (Cole Eye); K23-EY022947-01A1 (JPE)
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 366 – F0197. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Justis P Ehlers, Leina Lunasco, Sari Yordi, Hasan Cetin, Kubra Sarici, Thuy K Le, Katherine E Talcott, Robert Zahid, Joanne Hu, Xiangyi Meng, Peter K Kaiser, Arshad M. Khanani, Sunil K Srivastava; The Impact of Compartmental Exudative Volatility on Visual Acuity Outcomes in Neovascular AMD. Invest. Ophthalmol. Vis. Sci. 2022;63(7):366 – F0197.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Greater volatility of retinal thickness during anti-VEGF therapy has been associated with poorer visual acuity outcomes in eyes with neovascular age-related macular degeneration (nAMD). This post hoc analysis of the HAWK study examined whether specific exudative compartmental volatility (e.g., intraretinal fluid [IRF], subretinal fluid [SRF], and subretinal hyperreflective material [SHRM]) was associated with visual outcomes.

Methods : The HAWK study was a randomized phase 3 study in patients with nAMD (NCT02307682). Six hundred fifty-two eyes in the brolucizumab 6 mg and aflibercept 2 mg arms were included in the post hoc analysis. IRF, SRF, and SHRM volume was measured using a machine-learning enhanced feature-extraction platform with manual correction, as needed. For each eye, the standard deviation (SD) of the volume of each exudative compartment (IRF, SRF, and SHRM) was calculated from Week 12 to Week 56 (i.e., following the initial loading phase and representing the visit-to-visit variability). For each exudative compartment, eyes with SDs ≤25th percentile and ≥75th percentile were considered to have low and high volatility, respectively. The effect of volatility on mean change in best corrected visual acuity (BCVA) was examined from Week 12 at Week 56.

Results : Eyes with high SRF volatility demonstrated significantly worse visual outcomes compared to eyes with low SRF volatility (n=163, mean change=-2.18 letters vs n=314, mean change=+1.35 letters, respectively; P=0.0044). Similarly, eyes with high IRF volatility (n=163, mean change=-2.63 letters; P<0.0001) and eyes with low IRF volatility (n=367, mean change=+2.30 letters) had significant differences in change in visual acuity. Finally, there was also a significant difference in change in BCVA between eyes with high SHRM volatility (n=163, mean change=-2.47 letters; P=0.0001) and eyes with low SHRM volatility (n=166, mean change=+1.97 letters).

Conclusions : High volatility of each exudative parameter, including SRF, was associated with poorer visual outcomes. This suggests that identifying exudative fluctuation and potentially stabilizing that volatility may be important in maximizing visual acuity outcomes.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×